Defining a standardized core data set for pregnancy registers in rheumatic diseases - an European approach

Meissner Y¹, Strangfeld A¹, Costedoat-Chalumeau N^{2,3}, Förger F⁴, Molto A³, Wallenius M⁵, Fischer-Betz R⁶





Sweden:

Faculty of Medicine
and Health Sciences

Department of neuromedicine
and Movement Science



Patient representative: 3%



¹German Rheumatism Research Centre Berlin, Germany, ²Université Paris-Descartes, Internal medicine department, Paris, France, ³Hopital Cochin, Paris, France, ⁴University Hospital and University of, Bern, Switzerland, ⁵University Hospital and Norwegian University of Science and Technology, Trondheim, Norway, ⁶Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University, Düsseldorf, Germany

ACR 2018 2426

Male:

Conclusions

The majority of the invited European experts participated in the first round of the Delphi process. A total of 77 data items reached the consensus-in status, meaning that \geq 70% of the experts rated the item as critically important to be included in a core data set for pregnancy registers in rheumatology. However, results are only preliminary and final results are expected at the beginning of 2019.

Background & Objectives

Robust data on the outcomes of pregnancy and influence of drug exposure in various inflammatory rheumatic diseases (IRD) are needed. Joint analyses of data from different sources could overcome the issue of small study sample sizes in single databases. A prerequisite for collaborative analyses would be a common data set, collected from each of the collaborators.

Objective: The objective was to develop a core data set for observational research to measure pregnancy course and outcomes of women with underlying IRD.

Patients & Methods


The European Network of Pregnancy registers in rheumatology (EuNeP) consists of scientists who run pregnancy registers, namely EGR2 (France), RePreg (Switzerland), REVNATUS (Norway) and Rhekiss (Germany). During a face-to-face meeting involving all principal investigators of the mentioned registers, the scope and core areas of the core data set have been developed according to COS-STAD recommendations¹ by consensus. Consensus about the importance of each data item to be included in the final core data set is going to be reached by applying a 2-step Delphi survey. For each item, the importance must be rated on a numeric scale from 1 to 9. According to response rates, items were categorized into consensus-in, consensus-out and equivocal.

1 Kirkham et al. PLoS medicine. 2017;14(11):e1002447.

Funding: This work was supported by a research grant from FOREUM Foundation for Research in Rheumatology.

Results

The initial **list of data items** within the 3 core areas (Maternal information, Pregnancy, Medication) possibly relevant for pregnancy registers **included 143 items** and was generated based on (I) data items already collected by registers participating in EuNeP, (II) a systematic literature search and (III) results of a survey amongst 3 patient representatives. Delphi round 1 has already been taken place. Of the **invited 71 experts allover Europe**, **63 (89%) completed Delphi round 1**. Characteristics are given in figure 1.



In Delphi round 1, **77 data items reached the consensus-in status** (≥ 70% of participants rate the item as critical (scores 7-9)), no item reached the consensus-out status (≥ 70% of participants rate the item as not import (scores 1-3)) and 66 items were rated as equivocal (items that are neither in consensus-in nor in consensus-out). All items rated as consensus-in are presented in figure 2. Of note, these results are preliminary. For the final core data set, results of Delphi round 2 and - if necessary - of a further voting will be considered. Delphi round 2 will take place at the end of 2018.

Austria:

Figure 2: Scope, core areas and answering scores of Delphi round 1 (only data items that reached consensus-in status are presented).

SCOPE: To develop a standardized core data set for data collection in prospective observational research and clinical care of pregnant women with IRD. All interventions the women receive will be covered. Patients should be enrolled at the earliest possible moment during pregnancy, and data should ideally be collected once every trimester.

